KIMS Hospitals launches cutting-edge Neurosciences Institute in Mahadevapura

Lupin wins USFDA nod for generic Dapagliflozin tablets

Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market

Aurobindo gets USFDA approval for Dapagliflozin with 180-day exclusivity

Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size

Zydus gets USFDA final approval for generic Dapagliflozin with 180-day shared exclusivity

Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility

Merck expands Bengaluru plant to strengthen global filtration supply chain

New filtration lines will boost global drug supply and strengthen India’s role in Merck’s manufacturing network

Symeres and Ambagon team up to target ‘undruggable’ proteins in colorectal cancer

Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies

MedGenome’s RNA-based NGS study sharpens sarcoma diagnosis, alters treatment in 25% cases

India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases

World Health Day: Late diagnosis, rising lifestyle diseases put young India at risk

Sharp increase in diabetes, hypertension and fatty liver in 30–50 age group

The Semaglutide Surge: How a diabetes therapy sparked India’s weight loss wave

As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact

Apollo report warns India’s silent health risks are striking earlier among young adults

Health of the Nation 2026, based on over 3 million assessments, finds rising diabetes, obesity, and hidden cardiac risks in under-30s and working professionals